Use of a combination of biomarkers in serum and urine to improve detection of prostate cancer

World Journal of Urology

Volumn 28, Issue 6, 2010, Pages 681-686

  Prior, Celia ^a   Guillen Grima, Francisco ^b   Robles, Jose E ^b   Rosell, David ^b   Fernandez Montero, Jose M ^b   Agirre, Xabier ^a   Catena, Raúl ^a   Calvo, Alfonso ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

AMACR; Biomarkers; Methylation; MMP 2; Prostate cancer; PSA

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; ALPHA-METHYLACYL-COA RACEMASE; GELATINASE A; GLUTATHIONE TRANSFERASE P1; GSTP1 PROTEIN, HUMAN; ISOMERASE; PROSTATE SPECIFIC ANTIGEN; RASSF1 PROTEIN, HUMAN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; BLOOD; HUMAN; MALE; METABOLISM; METHYLATION; MIDDLE AGED; PREDICTIVE VALUE; PROSTATE TUMOR; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; URINE;

ADULT; AGED; AGED, 80 AND OVER; GLUTATHIONE S-TRANSFERASE PI; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; METHYLATION; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RACEMASES AND EPIMERASES; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 78049465549     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-010-0583-x     Document Type: Article

References (21)

1. Lilja H, Ulmert D, Vickers AJ (2008) Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 8(4): 268-278.
2. Loeb S, Catalona WJ (2008) What to do with an abnormal PSA test. Oncologist 13(3): 299-305.
3. Thompson IM, Chi C, Ankerst DP et al (2006) Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 98(16): 1128-1133.
4. Thompson IM, Pauler DK, Goodman PJ et al (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4. 0 ng per milliliter. N Engl J Med 350(22): 2239-2246.
5. Aus G, Damber JE, Khatami A, Lilja H, Stranne J, Hugosson J (2005) Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study. Arch Intern Med 165(16): 1857-1861.
6. Ulmert D, Serio AM, O'Brien MF et al (2008) Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. J Clin Oncol 26(6): 835-841.
7. Djavan B, Margreiter M (2007) Biopsy standards for detection of prostate cancer. World J Urol 25(1): 11-17.
8. Laxman B, Morris DS, Yu J et al (2008) A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res 68(3): 645-649.
9. Sreekumar A, Laxman B, Rhodes DR et al (2004) Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer. J Natl Cancer Inst 96(11): 834-843.
10. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM (2000) Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18(5): 1135-1149.
11. Stearns ME, Stearns M (1996) Immunohistochemical studies of activated matrix metalloproteinase-2 (MMP-2a) expression in human prostate cancer. Oncol Res 8(2): 63-67.
12. Costa VL, Henrique R, Jeronimo C (2007) Epigenetic markers for molecular detection of prostate cancer. Dis Markers 23(1-2): 31-41.
13. Hoque MO, Topaloglu O, Begum S et al (2005) Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol 23(27): 6569-6575.
14. Jeronimo C, Usadel H, Henrique R et al (2002) Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology 60(6): 1131-1135.
15. Bensalah K, Lotan Y, Karam JA, Shariat SF (2008) New circulating biomarkers for prostate cancer. Prostate Cancer Prostatic Dis 11(2): 112-120.
16. Shah RB, Mehra R, Chinnaiyan AM et al (2004) Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 64(24): 9209-9216.
17. Tinzl M, Marberger M, Horvath S, Chypre C (2004) DD3PCA3 RNA analysis in urine-a new perspective for detecting prostate cancer. Eur Urol 46(2): 182-186 (discussion 7).
18. Henrique R, Jeronimo C (2004) Molecular detection of prostate cancer: a role for GSTP1 hypermethylation. Eur Urol 46(5): 660-669 (discussion 9).
19. Lazcoz P, Munoz J, Nistal M, Pestana A, Encio I, Castresana JS (2006) Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma. BMC Cancer 6: 254.
20. Tokumaru Y, Harden SV, Sun DI, Yamashita K, Epstein JI, Sidransky D (2004) Optimal use of a panel of methylation markers with GSTP1 hypermethylation in the diagnosis of prostate adenocarcinoma. Clin Cancer Res 10(16): 5518-5522.
21. Morgia G, Falsaperla M, Malaponte G et al (2005) Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer. Urol Res 33(1): 44-50.